Aldeyra Therapeutics (ALDX) Change in Accured Expenses (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Change in Accured Expenses of -$1.2 million for Q1 2026, down 119.61% on a QoQ basis from -$564859.0 in Q4 2025, and up 75.99% year-over-year from -$704855.0 in Q1 2025.
Aldeyra Therapeutics (ALDX) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Change in Accured Expenses history runs 14 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- Quarterly Change in Accured Expenses rose 75.99% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 268.34% YoY) and the FY2025 annual result came in at -$6.3 million, down 226.59% from the prior year.
- Change in Accured Expenses was -$1.2 million for Q1 2026 at Aldeyra Therapeutics, down from -$564859.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.0 million in Q3 2024 and bottomed at -$5.2 million in Q1 2025.
- A 5-year average of -$555701.7 and a median of -$564859.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 4373.66% — and 2025, when it tumbled 1148.53%.
- Aldeyra Therapeutics' Change in Accured Expenses stood at $2.5 million in 2022, then tumbled by 102.52% to -$62147.0 in 2023, then surged by 3023.13% to $1.8 million in 2024, then slumped by 131.09% to -$564859.0 in 2025, then plunged by 119.61% to -$1.2 million in 2026.
- Business Quant data shows ALDX's Change in Accured Expenses at -$1.2 million in Q1 2026, -$564859.0 in Q4 2025, and -$795365.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | -16.74 Mn |
| 10 | Aldeyra Therapeutics | 95.35 Mn | 95.35 Mn | - | -1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.24 Mn |
| Mar 31, 2026 | -1.24 Mn |
| Dec 31, 2025 | -564,859.00 |
| Dec 31, 2025 | -564,859.00 |
| Sep 30, 2025 | -795,365.00 |
| Sep 30, 2025 | -795,365.00 |
| Jun 30, 2025 | 191,018.00 |
| Jun 30, 2025 | 191,018.00 |
| Mar 31, 2025 | -5.17 Mn |
| Mar 31, 2025 | -5.17 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Jun 30, 2024 | -351,150.00 |
| Jun 30, 2024 | -351,150.00 |
| Mar 31, 2024 | 492,710.00 |
| Mar 31, 2024 | 492,710.00 |
| Dec 31, 2023 | -62,147.00 |
| Dec 31, 2023 | -62,147.00 |